Stockscreener 앱 받기
5.36
6.46%
-0.37
시간 외 거래:
5.35
-0.01
-0.19%
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance UK
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
EcoR1 Capital LLC Makes New $3.24 Million Investment in Prelude Therapeutics Incorporated $PRLD - MarketBeat
PRLD|Prelude Therapeutics Inc|Price:4.640| - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRLD|Prelude Therapeutics Inc|Price:3.830|Chg%:-0.100 - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Prelude Therapeutics Incorporated Revenue Breakdown – NASDAQ:PRLD - TradingView
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics stock trades around recent lows as clinical pipeline spending weighs on results - Ad-hoc-news.de
Enterprise value to EBITDA forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Enterprise value to revenue forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - Yahoo Finance
Research Analysts Offer Predictions for PRLD Q2 Earnings - MarketBeat
H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Canada
JAK2 inhibitors reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79% - MarketsMojo
Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.com - Investing.com Canada
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2000 Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell Microcap Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 3000E Index - marketscreener.com
MapLight Therapeutics appoints two directors to board - Investing.com UK
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
MapLight Therapeutics Announces Changes to Board of Directors - The Manila Times
Prelude Therapeutics (PRLD) Edges Higher, Approaches Key Resistance at $4.60Overvalued Signals - dars.gov.et
Prelude Therapeutics (PRLD) Edges Lower as Stock Tests Key Support LevelADD Alert - dars.gov.et
PRLD Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Institutional Confidence - TradingKey
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Moomoo
PRLD Q1 2026 Earnings: Narrower Net Loss Beats EstimatesNegative Surprise Momentum - newsline.com
[Form 4] Prelude Therapeutics Inc Insider Trading Activity - Stock Titan
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike - Stock Titan
Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay - Stock Titan
PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote - TradingView
PRLD: All proposals passed, directors elected, auditor ratified, and no shareholder questions submitted - TradingView
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - BioSpace
PRLD Stock Price, Quote & Chart | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs - Bez Kabli
Prelude Therapeutics Reports Earnings and Advances Precision Oncology Pipeline - asatunews.co.id
Prelude Therapeutics Reports First Quarter Financial Results and Pipeline Expansion - HarianBasis.co
Goldman Sachs Initiates Coverage on Prelude Therapeutics: What It Could Mean for InvestorsEPS Growth Report - newsline.com
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics Drops 5.5% as Biotech Sector Faces Headwinds – Key Support Levels in FocusBollinger Squeeze - The Legal Advocate
PRLDPrelude Therapeutics Inc Stock Price and Quote - Finviz
Prelude Therapeutics (PRLD) Extends Gains: Support Holds, Resistance in FocusFear Greed Index - The Legal Advocate
PRLD Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOne-Time Gain Impact - newsline.com
0.03%
0.33%
자본화:
|
볼륨(24시간):